28 days
Time to First Decision

Medicines, Volume 11, Issue 3

2024 March - 2 articles

Cover Story: Pharmacogenomics (PGx) can facilitate the transition to patient-specific drug regimens and thus improve their efficacy and reduce toxicity. The aim of this study was to evaluate the overlap of PGx classification for drug absorption, distribution, metabolism, and elimination (ADME)-related genes in the U.S. Food and Drug Administration (FDA) PGx labeling and in the Clinical Pharmacogenetics Implementation Consortium (CPIC) database. FDA-approved drugs and PGx labeling for ADME genes were identified in the CPIC database. Drugs were filtered by their association with ADME (pharmacokinetics)-related genes, PGx FDA labeling class, and CPIC evidence level. FDA PGx labeling was classified as either actionable, informative, testing recommended, or testing required, and varying CPIC evidence levels as either A, B, C, or D. View this paper

Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
You may sign up for email alerts to receive table of contents of newly released issues.
PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (2)

Select all

Article

1 Citations

2,948 Views

11 Pages

Triple Silencing of HSP27, cFLIP, and CLU Genes Promotes the Sensitivity of Doxazosin-Induced Apoptosis in PC-3 Prostate Cancer Cells

Jeong Man Cho,
Sojung Sun,
Eunji Im,
Hyunwon Yang and
Tag Keun Yoo

Medicines2024, 11(3), 7;https://doi.org/10.3390/medicines11030007

21 February 2024

Background: This study investigated how the expression of heat shock protein 27 (HSP27), cellular FLICE-like inhibitory protein (cFLIP), and clusterin (CLU) affects the progression of cancer cells and their susceptibility to doxazosin-induced apoptos...

Full Article

Article

4 Citations

4,976 Views

16 Pages

ADME Gene-Related Pharmacogenomic Labeling of FDA-Approved Drugs: Comparison with Clinical Pharmacogenetics Implementation Consortium (CPIC) Evidence Levels

Subrata Deb,
Robert Hopefl,
Anthony Allen Reeves and
Dena Cvetkovic

Medicines2024, 11(3), 6;https://doi.org/10.3390/medicines11030006

20 February 2024

Pharmacogenomics (PGx) can facilitate the transition to patient-specific drug regimens and thus improve their efficacy and reduce toxicity. The aim of this study was to evaluate the overlap of PGx classification for drug absorption, distribution, met...

Full Article

Get Alerted

Add your email address to receive forthcoming issues of this journal.

Medicines - ISSN 2305-6320

Imprint

Download Flyer